CCI Gives Approval To Carlyle Group's 20% Buy In Piramal Pharma

Published date: .

The Competition Commission of India (CCI) on Friday said it had approved acquisition of 20 per cent stake in Ajay Piramal-led Piramal Pharma by US-based global investment firm Carlyle Group.

Piramal Enterprises, in a regulatory filing, in June had said Carlyle Group Inc would buy 20 per cent stake in Piramal Pharma for around $490 million (over Rs 3,700 crore).

The estimated equity capital investment for Carlyle's 20 per cent stake in Piramal Pharma would amount to around $490 million, it said.

The final amount of equity investment will depend on the net debt, exchange rate and performance against the pre-agreed conditions at the time of closing of the deal, it said.